Hospira, Inc.

Hospira Challenges Cubist Antibiotic Patents

Abbott, Hospira Win Appellate Affirmation in Spinoff Retirement Lawsuit

Hospira names Richard Davies Chief Commercial Officer

As shortages increase, drugmakers feel the heat

FDA dings Hospira for 'misleading' ads for blood drug

FDA dings Hospira for 'misleading' ads for blood drug

Clinical Product and Knowledge Lead - Hospira, Inc - Salt lake City, UT

Hospira Launches Phase III Trial for Biosimilar of Amgen’s Epogen

Baxter Worth $65 Given Hospira's Shocking Troubles

Why Covidien Will Surge 50% As Hospira Struggles

UBS: 8 Pharma Stocks to Watch

Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections

Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Hospira, Inc.

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Hospira, Inc.

Time for drugs firms to stop making a killing | Ford Vox

U.S. Medical Technology sector downgraded at Goldman

Problems at Hospira’s Rocky Mount Plant Costly But ‘Fixable,’ CEO Says

Hospira Announces Start Of U.S. Phase III Biosimilar EPO Clinical Program

Hospira Starts Phase 3 of Biosimilar EPO Study

Hospira 483 likely to extend overhang on shares, says Citigroup

Raymond James Downgrades Hospira (HSP) to Market Perform

Hospira downgraded to Market Perform from Outperform at Raymond James

DURECT Announces Top-Line Data From BESST (POSIDUR® U.S. Pivotal Phase III Trial)

Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program

Hospira commences U.S. Phase 3 Biosimilar EPO clinical program

Hospira (HSP) Enrolls First Patient in Biosimilar EPO Phase III

Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program

Pancuronium pandemonium as doctors slam Hospira for execution injections

Hospira pressured by doctors over drug used in executions

[Correspondence] An open letter to Michael Ball, Chief Executive of Hospira Pharmaceuticals – Response from Hospira

[Correspondence] An open letter to Michael Ball, Chief Executive of Hospira Pharmaceuticals

DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)

Hospira Upped to Neutral

Hospira Upped to Neutral - Analyst Blog

CORRECTING and REPLACING Glancy Binkow & Goldberg LLP Announces That a Class Action Lawsuit Against Hospira, Inc. Has Been Filed and the Lead Plaintiff Deadline is January 20, 2012

JP Morgan's major/specialty pharmaceuticals analyst holds a conference call

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Hospira, Inc.

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Hospira, Inc.

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Hospira, Inc.